Privia Health Group, Inc. $PRVA Shares Purchased by Squarepoint Ops LLC

Squarepoint Ops LLC boosted its holdings in Privia Health Group, Inc. (NASDAQ:PRVA) by 313.2% in the 2nd quarter, HoldingsChannel reports. The fund owned 198,763 shares of the company’s stock after acquiring an additional 150,655 shares during the quarter. Squarepoint Ops LLC’s holdings in Privia Health Group were worth $5,114,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of PRVA. GAMMA Investing LLC grew its stake in shares of Privia Health Group by 14.0% during the 2nd quarter. GAMMA Investing LLC now owns 4,819 shares of the company’s stock worth $124,000 after purchasing an additional 592 shares during the period. PNC Financial Services Group Inc. grew its position in Privia Health Group by 8.8% during the first quarter. PNC Financial Services Group Inc. now owns 10,361 shares of the company’s stock worth $213,000 after buying an additional 840 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in Privia Health Group by 48.1% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,739 shares of the company’s stock valued at $70,000 after buying an additional 889 shares in the last quarter. ProShare Advisors LLC lifted its position in shares of Privia Health Group by 4.1% during the 4th quarter. ProShare Advisors LLC now owns 22,576 shares of the company’s stock valued at $535,000 after acquiring an additional 898 shares during the period. Finally, Vanguard Personalized Indexing Management LLC lifted its position in shares of Privia Health Group by 5.9% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 16,250 shares of the company’s stock valued at $385,000 after acquiring an additional 903 shares during the period. Institutional investors and hedge funds own 94.48% of the company’s stock.

Insider Activity

In other news, Director Matthew Morris sold 53,722 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $27.24, for a total value of $1,463,387.28. Following the completion of the transaction, the director owned 68,188 shares of the company’s stock, valued at $1,857,441.12. The trade was a 44.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO David Mountcastle sold 21,275 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $27.67, for a total transaction of $588,679.25. Following the transaction, the chief financial officer directly owned 164,853 shares in the company, valued at $4,561,482.51. The trade was a 11.43% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 327,886 shares of company stock worth $8,628,256 over the last ninety days. 5.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

PRVA has been the topic of a number of research reports. Citigroup restated a “buy” rating on shares of Privia Health Group in a report on Thursday, July 23rd. Barclays reduced their price objective on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating for the company in a report on Tuesday, May 26th. Weiss Ratings upgraded Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, July 2nd. Zacks Research raised Privia Health Group from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 5th. Finally, Canaccord Genuity Group set a $32.00 target price on shares of Privia Health Group in a research report on Friday, August 7th. Eleven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Privia Health Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

Privia Health Group Stock Up 0.2%

Shares of NASDAQ:PRVA opened at $20.42 on Friday. The company has a market capitalization of $2.61 billion, a P/E ratio of 97.24 and a beta of 0.87. Privia Health Group, Inc. has a 52-week low of $19.53 and a 52-week high of $28.82. The stock’s fifty day simple moving average is $23.36 and its 200-day simple moving average is $23.09.

Privia Health Group (NASDAQ:PRVA) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.12. Privia Health Group had a return on equity of 3.52% and a net margin of 1.19%.The firm had revenue of $632.63 million during the quarter, compared to analysts’ expectations of $597.33 million. During the same quarter last year, the business posted $0.24 EPS. The firm’s quarterly revenue was up 21.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Privia Health Group, Inc. will post 0.27 earnings per share for the current year.

Privia Health Group Profile

Privia Health Group, Inc is a national physician enablement company that supports independent medical groups in delivering value-based care. Through its technology-enabled platform, the company provides administrative, clinical, and operational services designed to help physicians manage patient populations, improve care coordination, and participate in contracts with health plans and employers.

Privia’s services include practice management, electronic health record and data analytics tools, revenue-cycle support, marketing, recruiting, and other nonclinical business functions.